Table 4: Number (%) of patients who discontinued the study grouped by primary reason (ITT population).

Oral rabeprazole group ( )IV omeprazole group ( )

Loss to followup at 6 weeks21 (38.9%)14 (26.9%)
Detection of exclusion criteria after enrollment*4 (7.4%)3 (5.8%)
Patient request01 (1.9%)
Protocol violation01 (1.9%)

Total25 (46.3%)19 (36.5%)

ITT: intention-to-treat; IV: intravenous.
*Detection of exclusion criteria after enrollment included lung cancer, stomach cancer at another site, bleeding of a gastric adenoma, Billroth II subtotal gastrectomy, and bleeding of a duodenal submucosal tumor.